In development for atopic dermatitis, seborrheic dermatitis, and scalp and body psoriasis.
Topical roflumilast is a selective and highly potent,* nonsteroidal phosphodiesterase 4 (PDE4) inhibitor being investigated for the once-daily treatment of atopic dermatitis, seborrheic dermatitis, and scalp and body psoriasis.1
*In vitro data. Clinical efficacy claims cannot be made.
PDE4 is an enzyme that contributes to immune-mediated dermatologic conditions.
Inhibition of PDE4 modulates the immune response by downregulating key inflammatory cytokines such as IFN-γ, TNF-α, IL-4, IL-17, and IL-23; restoring the skin barrier balance, and decreasing inflammatory response.
IFN = interferon, IL = interleukin, TNF = tumor necrosis factor.
Roflumilast is a PDE4 inhibitor being investigated in topical cream and foam formulations.
1. Dong et al. J Pharmacol Exp Ther. 2016;358(3):413-422. 2. Li et al. Front Pharmacol. 2018;9:1048. 3. Data on File. Arcutis Biotherapeutics, Inc. 4. Berk et al. Presented at: The Society for Investigative Dermatology Annual Meeting; May 18-22, 2022; Portland, OR.